Skip to content
drillr.ai
Sign up

SPRC

SciSparc Ltd.

NASDAQ · Healthcare · Biotechnology · IL

$5.29
+3.12%
Ask drillr

  • Sep 2, 2026, 12:10 UTC

    SciSparc's subsidiary NeuroThera Labs announced it is pursuing FDA Orphan Drug Designation for its drug candidate SCI-110 for treating adult Tourette Syndrome, and engaged government affairs firm RK Strategies.

    Source:

  • Aug 31, 2026, 20:03 UTC

    SciSparc's subsidiary NeuroThera Labs announced continued advancement in participant enrollment for the clinical trial of its SCI-210 treatment for autism spectrum disorder symptoms.

    Source:

  • Aug 28, 2026, 21:05 UTC

    NeuroThera Labs Inc. announced a share consolidation of its outstanding common shares on a 1-for-14 basis, effective after a shareholder resolution passed on January 8, 2026.

    Source:

  • Aug 27, 2026, 12:00 UTC

    NeuroThera Labs Inc. engaged Dr. Reuter Investor Relations to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026.

    Source:

  • Aug 18, 2026, 12:06 UTC

    SciSparc's subsidiary NeuroThera Labs completed a C$5.4 million financing, with SciSparc investing C$2.7 million and holding approximately 44.6% of NeuroThera's shares.

    Source:

  • Aug 12, 2026, 12:02 UTC

    NeuroThera Labs Inc. announced that the Japanese Patent Office granted it a patent for its pharmacological combination titled 'Compositions and Methods for Potentiating Derivatives of 4-Aminophenols'.

    Source:

  • Aug 5, 2026, 12:05 UTC

    NeuroThera Labs initiated its Phase IIb clinical trial at Yale Child Study Center for SCI-110, a cannabinoid-based drug candidate for Tourette Syndrome.

    Source:

  • Jul 29, 2026, 12:32 UTC

    SciSparc's subsidiary NeuroThera Labs completed internal validation of a proprietary quantum sampling workflow platform for clinical trials data analysis.

    Source:

  • Jul 27, 2026, 12:25 UTC

    SciSparc Ltd. announced its decision to target the agentic AI market and formed a scientific advisory board for AI and cybersecurity.

    Source:

  • Jul 15, 2026, 12:31 UTC

    NeuroThera Labs Inc. initiated a Phase IIb clinical trial at Hannover Medical School in Germany for its SCI-110 treatment candidate for Tourette Syndrome.

    Source:

  • Jun 3, 2026, 21:15 UTC

    Neurothera Labs Inc. closed its acquisition of a 54.01% majority stake in CliniQuantum Ltd. by issuing 56,600,000 common shares valued at approximately $9,459,954.20.

    Source: